Clinical Management Issues (Oct 2015)

Long lasting octreotide LAR therapy in non functioning pancreatic neuroendocrine carcinoma

  • Ivan Lolli,
  • Antonio Logroscino,
  • Simona Vallarelli,
  • Maria A. Monteduro,
  • Antonella Gentile,
  • Giuseppe Troccoli

DOI
https://doi.org/10.7175/cmi.v4i1S.1067
Journal volume & issue
Vol. 4, no. 1S
pp. 19 – 25

Abstract

Read online

Non functioning endocrine pancreatic tumors (NF-PETs) have absent or low hormone secretion without symptoms and constitue ~60% of PETs. At diagnosis more than 50% of patients have liver metastases and almost 40% are not candidates for radical surgery because of either locally advanced disease or unresectable metastases. We described the case of a 47-year-old woman with a pancreatic carcinoma with secondarism in the liver not suitable for radical surgery. Histological test of liver metastases showed positivity for endocrine well-differentiated non functioning carcinoma expressing receptors for somatostatin with very low proliferation index (Ki67 < 2%). After this diagnosis she started a specific treatment with octreotide analogues which achieved durable stabilization of the disease.

Keywords